Chugai Seiyaku Kabushiki Kaisha

Other

F. Hoffmann-la Roche Ag

Sakai Toshiyuki

Toshihiro Aoki

Fumio Watanabe

Naoki Harada

Masahiro Sakaitani

Hitoshi Iikura

Masayuki Matsushita

Sawako Ozawa

Noriyuki Furuichi

Ikumi Hyoudoh

Pil-Su Ho

Yasushi Tomii

Kenji Takanashi

Kenichi Kawasaki

Hiroki Nishii

Toshiyuki Sakai

Jun Ohwada

Kazuo Hattori

Yoshiaki Isshiki

Satoshi Niizuma

Kihito Hada

Yoshito Nakanishi

Hirosato Ebiike

Ikumi Hyodo

Masami Kochi

Kimitaka Nakama

Masaki Tomizawa

Aiko Suge

Takashi Chiba

Hiroyuki Shimamura

Natsuki Kobayashi

The present disclosure provides, for example, a compound represented by the general formula below or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of the compound or salt: wherein X, X, Xand Xare each independently —CR═ or N═, Ris, for example, a halogen atom, Ris, for example, —S(═O)—NH—R, Ris, for example, a Calkyl group, Ris, for example, a hydrogen atom, Ris, for example, a halogen atom, Ris, for example, a hydrogen atom, and Ris, for example, a cyclopropyl group. The compounds, salts or solvates provided by the present disclosure exhibit high RAF/MEK complex-stabilizing activity and can be used for the treatment or prevention of cell proliferative disorders, particularly cancers.

Arylamide derivative having antitumor activity

An objective of the present invention is to provide low-molecular-weight compounds that can inhibit Src family kinases. The present invention relates to compounds represented by general formula (I) or pharmacologically acceptable salts thereof. In the formula, Aris optionally substituted Carylene or 5- to 10-membered heteroarylene, and Aris optionally substituted Caryl or 5- to 10-membered heteroaryl. Rand Rare defined as described in the specification.

Aminopyrazole derivatives

The present invention provides a p27 protein inducing agent comprising a compound represented by general formula (11) below or pharmaceutically acceptable salt thereof as an active ingredient: wherein G, G, Gand Gare each independently selected from &#x2014;N&#x2550; etc., Ring Gis selected from divalent aryl etc., A is selected from amino etc., Gis selected from oxygen etc., Gis selected from oxygen etc., Gis selected from &#x2014;CH&#x2014; etc., and Ris selected from Calkyl etc.

p27 protein inducer

The present invention provides a compound represented by general formula (1) below or a pharmaceutically acceptable salt thereof: wherein: X is selected from heteroaryl etc., Yand Yare selected from &#x2014;N&#x2550; etc., Yand Yare selected from &#x2014;CH&#x2550; etc., A is selected from sulfamide etc., Ris selected from hydrogen etc., and Ris selected from Calkyl etc. The compound or salt has sufficiently high antitumor activity, and is useful in the treatment of cell proliferative disorders, particularly cancers. The present invention also provides a pharmaceutical composition containing the compound or salt as an active ingredient.

Coumarin derivative having antitumor activity

Growing community of inventors

Kamakura, Japan

Toshihiro Aoki